Elastin Targeted Drug Delivery for Treating Elastin Degenerative Diseases (2012-048)

Market Overview:

This targeted drug delivery approach uses micro-sized drug carriers with elastin antibodies that recognize, attach, and deliver compounds to prevent enzymatic degradation of elastin in diseased tissue. Enzymatic degradation of elastin tissue is the primary cause of chronic obstructive pulmonary disease (COPD) and abdominal aortic aneurysm (AAA). COPD is the third leading cause of death in the U.S. and there are over 3 million new cases of AAA each year. Currently, damaged elastin is managed via surgical procedures like endovascular surgery. While most procedures are minimally invasive, its lifespan has yet to be determined and does not directly improve the condition of elastic tissue at the damaged site. Clemson University researchers have developed drug carriers designed to target damaged elastin by a simple IV injection. The elastin antibody drug carriers bind to exposed elastin and deliver therapeutic compounds to preserve and regenerate elastin tissue.

Application                                                                                               Stage of Development

Treating COPD, cardiovascular aneurysms; elastin regeneration             In vivo animal studies


• Targets extracellular matrix proteins and not cellular proteins, boosting efficacy and minimizing systemic effects

• Inhibits or reverses progression of elastin degeneration, overcoming barriers of current treatments

Technical Summary

This approach utilizes drug-loaded nanoparticles coated with elastin antibodies to correct and prevent elastin degradation. These particles are coated with receptors that bind specifically to damaged or exposed elastin molecules, thus increasing the residence time of the particles inside the body and improving the drug efficacy at the degeneration site. The particles also release a polyphenol (PGG) that works to prevent degradation from occurring while also regenerating elastic tissue.  These particles can be delivered intravenously, marking a significant advantage over surgical treatments. The approach demonstrates effectiveness in targeting in vivo in number of animal models of the diseases such as AAA, COPD, arteriosclerosis, and skin disorders.

View printable PDF version of this technology


Inventors:                        Naren Vyavahare, Aditi Sinha

Patent Type:                    Utility

Serial Number:                13/929,140

CURF Ref:                      2012-048


Related Publications

Systemic Delivery of Nanoparticles Loaded with Pentagalloyl Glucose Protects Elastic Lamina and Prevents Abdominal Aortic Aneurysm in Rats.

Nosoudi N, Chowdhury A, Siclari S, Parasaram V, Karamched S, Vyavahare N.

J Cardiovasc Transl Res. 2016 Aug 19. [Epub ahead of print]

PMID: 27542007

Targeted drug delivery to emphysematous lungs: Inhibition of MMPs by doxycycline loaded nanoparticles.

Parasaram V, Nosoudi N, LeClair RJ, Binks A, Vyavahare N.

Pulm Pharmacol Ther. 2016 Aug;39:64-73. doi: 10.1016/j.pupt.2016.06.004. Epub 2016 Jun 25. No abstract available.

PMID: 27354173

Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles.

Nosoudi N, Nahar-Gohad P, Sinha A, Chowdhury A, Gerard P, Carsten CG, Gray BH, Vyavahare NR.

Circ Res. 2015 Nov 6;117(11):e80-9. doi: 10.1161/CIRCRESAHA.115.307207. Epub 2015 Oct 6.

PMID: 26443597

Targeted chelation therapy with EDTA-loaded albumin nanoparticles regresses arterial calcification without causing systemic side effects.

Lei Y, Nosoudi N, Vyavahare N.

J Control Release. 2014 Dec 28;196:79-86. doi: 10.1016/j.jconrel.2014.09.029. Epub 2014 Oct 5.

PMID: 25285609

Nanoparticle targeting to diseased vasculature for imaging and therapy.

Sinha A, Shaporev A, Nosoudi N, Lei Y, Vertegel A, Lessner S, Vyavahare N.

Nanomedicine. 2014 Jul;10(5):1003-12. doi: 10.1016/j.nano.2014.02.002. Epub 2014 Feb 22.

PMID: 24566276

Patent Information:
Biomedical Sciences
For Information, Contact:
Vincie Albritton
Deputy Director
Clemson University Research Foundation
Narendra Vyavahare
Aditi Sinha
Biomaterials - Cardiovascular
Drugs/Pharma - Drug Delivery
Medical Device
Molecular Therapies
Regenerative Medicine
© 2019. All Rights Reserved. Powered by Inteum